We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+38.74%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.72B
AUM Growth
+$518M
Cap. Flow
+$119M
Cap. Flow %
6.94%
Top 10 Hldgs %
67.52%
Holding
71
New
13
Increased
19
Reduced
9
Closed
13

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$43.8M
2
GILD icon
Gilead Sciences
GILD
+$30.4M
3
AZN icon
AstraZeneca
AZN
+$24.5M
4
ISRG icon
Intuitive Surgical
ISRG
+$20.7M
5
MRK icon
Merck
MRK
+$19.9M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$30.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.1M
3
RGNX icon
Regenxbio
RGNX
+$16.7M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$15.8M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.36%
2 Miscellaneous 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
26
Eli Lilly
LLY
$1T
$14.7M 0.86%
+45,500
New +$14.4M
ZNTL icon
27
Zentalis Pharmaceuticals
ZNTL
$360M
$12.6M 0.74%
583,357
+254,960
+78% +$6.97M
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.77B
$12.6M 0.73%
525,002
+111,574
+27% +$2.5M
EW icon
29
Edwards Lifesciences
EW
$49.7B
$12.2M 0.71%
+147,200
New +$14.2M
AKUS
30
DELISTED
Akouos Inc
AKUS
$10.2M 0.6%
1,515,074
– –
RCUS icon
31
Arcus Biosciences
RCUS
$3.63B
$9.98M 0.58%
+381,345
New +$10.1M
INZY
32
DELISTED
Inozyme Pharma
INZY
$9.8M 0.57%
3,655,308
– –
IDYA icon
33
IDEAYA Biosciences
IDYA
$3.7B
$9.77M 0.57%
+654,756
New +$8.5M
TVTX icon
34
Travere Therapeutics
TVTX
$6.24B
$9.72M 0.57%
394,678
+182,085
+86% +$4.7M
RXDX
35
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$8.25M 0.48%
139,774
-246,621
-64% -$11.3M
INBX
36
DELISTED
Inhibrx, Inc. Common Stock
INBX
$8.08M 0.47%
450,177
+302,242
+204% +$5.45M
NXTC icon
37
NextCure
NXTC
$36.9M
$7.35M 0.43%
222,655
– –
ACET icon
38
Adicet Bio
ACET
$89.3M
$7M 0.41%
30,748
-1,651
-5% -$419K
FULC icon
39
Fulcrum Therapeutics
FULC
$293M
$6.45M 0.38%
+797,262
New +$5.71M
INBX
40
PUT
DELISTED
Inhibrx, Inc. Common Stock
INBX
$6.28M 0.37%
+350,000
New +$6.31M
NCNA
41
NuCana
NCNA
$5.7M
$5.85M 0.34%
1,120
– –
KDNY
42
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$5.66M 0.33%
287,901
+11,292
+4% +$226K
RGNX icon
43
Regenxbio
RGNX
$576M
$5.66M 0.33%
213,959
-562,665
-72% -$16.7M
GRTX
44
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$5.37M 0.31%
3,083,712
– –
IMTX icon
45
Immatics
IMTX
$1.39B
$5.33M 0.31%
532,516
-761,587
-59% -$8.22M
ARQT icon
46
Arcutis Biotherapeutics
ARQT
$3B
$5.24M 0.31%
+274,330
New +$6.22M
AGEN
47
Agenus
AGEN
$309M
$5M 0.29%
124,189
+75,647
+156% +$3.86M
INSM icon
48
Insmed
INSM
$28.1B
$4.75M 0.28%
220,665
+213,295
+2,894% +$5.11M
BOLT icon
49
Bolt Biotherapeutics
BOLT
$7.09M
$4.08M 0.24%
137,722
– –
GERN icon
50
Geron
GERN
$899M
$2.78M 0.16%
1,189,208
-1,602,422
-57% -$3.59M
1
2
3

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q3 2022 Portfolio in Review

As of Q3 2022, Sofinnova Investments held 71 positions worth $1.72B, up 43% from $1.2B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments deployed $119M of net new capital in Q3 2022, opening 13 new positions and adding to 19 existing holdings. Its largest new stake was Gilead Sciences: 482,400 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regenxbio, an estimated $16.7M trimmed.

  • Sofinnova Investments's largest Q3 2022 buy was Gilead Sciences: 482,400 shares worth $29.8M.
  • Sofinnova Investments added most to Sanofi in Q3 2022, an estimated $43.8M increase.
  • Sofinnova Investments's biggest Q3 2022 reduction was Regenxbio, cutting an estimated $16.7M.
  • Sofinnova Investments fully exited Novo Nordisk in Q3 2022, selling an estimated $30.5M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.72B portfolio in Q3 2022.
  • Sofinnova Investments opened 13 new positions and closed 13 in Q3 2022.
  • Sofinnova Investments's portfolio value rose 43% quarter-over-quarter to $1.72B.

Based on Sofinnova Investments's 13F filing for Q3 2022, filed 8 Nov 2022.